The data reported here are useful in planning further definitive studies that will enable optimization of HER2-directed therapy for future phase III trials and shed important light on the heterogeneity of HER2+ breast cancer and its impact on response to targeted therapy. The gene discussed is ERBB2; the disease is breast carcinoma.